Factor VII deficiency: do all need replacement for cardiac surgery?

Asian Cardiovascular & Thoracic Annals
Fayaz Mohammed KhaziObaid Al-Jassim

Abstract

In cardiac surgery, supplementation with recombinant factor VIIa is the treatment of choice for patients with factor VII deficiency, but overzealous administration can be associated with thromboembolic side-effects. A 53-year-old man with factor VII activity 15.2%, international normalized ratio 2.9, and acute thrombotic critical coronary anatomy, underwent coronary artery bypass surgery and a thoracotomy with decortication 5 months later. He was managed successfully without recombinant factor VIIa supplementation. This case demonstrates that current bedside and laboratory tests such as thromboelastography, prothrombin time or international normalized ratio, and factor VII activity may not predict replacement therapy in these patients.

Methods Mentioned

BETA
coronary artery bypass

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

JAMA : the Journal of the American Medical Association
Richard P DuttonThomas M Scalea
Haemophilia : the Official Journal of the World Federation of Hemophilia
M Karimi, R Shafieian
© 2022 Meta ULC. All rights reserved